SCHEMBL18317596

SCHEMBL18317596

O=C(NCc1ccccn1)Nc1ccc(Cc2ccc(NC(=O)NCc3ccccn3)cc2)cc1

nearest known ligand 0.80

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.80
NPC1 O15118 6/20 0.78
KMT2A Q03164 5/20 0.75
L3MBTL1 Q9Y468 1/20 0.75
SMN1; SMN2 Q16637 3/20 0.70
ALOX15 P16050 1/20 0.70
GLA P06280 1/20 0.66
MAPT P10636 1/20 0.66
HTT P42858 1/20 0.66
MEN1 O00255 2/20 0.65
CA12 O43570 1/20 0.64
CA1 P00915 1/20 0.64
CA2 P00918 1/20 0.64
CA9 Q16790 1/20 0.64
LMNA P02545 1/20 0.62
TSHR P16473 1/20 0.61
GAA P10253 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11618998 0.88 RAB9A (1.00) RAB9ANPC1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL18317283 0.86 CNR1 (0.76) RAB9ANPC1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL30818065 0.86 NPC1 (0.78) RAB9ANPC1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL20379728 0.86 NPC1 (0.78) RAB9ANPC1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL20380104 0.86 L3MBTL1 (1.00) RAB9ANPC1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL20379469 0.86 NPC1 (0.78) RAB9ANPC1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL23747452 0.84 CNR1 (0.66) RAB9ANPC1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL22103790 0.82 NPC1 (1.00) RAB9ANPC1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL175437 0.82 NPC1 (0.72) RAB9ANPC1KMT2AL3MBTL1SMN1; SMN2
SCHEMBL20379320 0.82 L3MBTL1 (0.74) RAB9ANPC1KMT2AL3MBTL1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2016209785-A1 UREA GELLANTS THE PROCTER & GAMBLE COMPANY (US) 2016-12-29 WO claimed
EP-3109233-A1 UREA GELLANTS The Procter and Gamble Company (US) 2016-12-28 EP claimed
US-20160369208-A1 UREA GELLANT THE PROCTER & GAMBLE COMPANY 2016-12-22 US claimed
US-10184096-B2 Urea gellant THE PROCTER & GAMBLE COMPANY (US) 2019-01-22 US disclosed
US-10184096-B2 Urea gellant THE PROCTER & GAMBLE COMPANY (US) 2019-01-22 US disclosed
WO-2016209785-A1 UREA GELLANTS THE PROCTER & GAMBLE COMPANY (US) 2016-12-29 WO disclosed
EP-3109233-A1 UREA GELLANTS The Procter and Gamble Company (US) 2016-12-28 EP disclosed
US-20160369208-A1 UREA GELLANT THE PROCTER & GAMBLE COMPANY 2016-12-22 US disclosed
US-20160369208-A1 UREA GELLANT THE PROCTER & GAMBLE COMPANY 2016-12-22 US disclosed
US-20160369208-A1 UREA GELLANT THE PROCTER & GAMBLE COMPANY 2016-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160369208-A1 UREA GELLANT UGP2, UGGT1, SLC14A1 RAB9A 2575/4885NPC1 1374/4885KMT2A 2308/4885
US-10184096-B2 Urea gellant UGP2, UGGT1, SLC14A1 RAB9A 2575/4885NPC1 1374/4885KMT2A 2308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.